Clinical Trial Update: Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ALK4290 for wet age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• ALK4290

Snippet

Sponsor: Alkahest, Inc. | Conditions: Wet Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2020-08-28